RRC ID 38312
Author Ha H, Lee HY, Lee JH, Jung D, Choi J, Song KY, Jung HJ, Choi JS, Chang SI, Kim C.
Title Formononetin prevents ovariectomy-induced bone loss in rats.
Journal Arch. Pharm. Res.
Abstract The major risk factor of postmenopausal osteoporosis is estrogen deficiency. Hormone replacement therapy is efficacious against osteoporosis, but it induces several significant adverse effects. In this study, therefore, we compared therapeutic potencies of three phytoestrogens: genistein, daidzein, and formononetin. Our result showed that in Saos-2 cells, formononetin and genistein (5 x 10(-7) M) treatment increased alkaline phosphatase activity by 33.0 +/- 5.8% and 21.1 +/- 4.0%. Genistein inhibited osteoclast formation in a dose-dependent manner. In OVX rats, formononetin-treated groups given 1 and 10 mg/kg/day displayed increased trabecular bone areas (TBAs) within the tibia. Genistein- and daidzein-treated groups also displayed increased tibial TBAs. TBAs of the lumbar vertebrae were higher in all treated groups than in the control group. In conclusion, formononetin as well as other isoflavones, such as daidzein and genistein, inhibited bone loss caused by estrogen-deficiency.
Volume 33(4)
Pages 625-32
Published 2010-4
DOI 10.1007/s12272-010-0418-8
PMID 20422373
MeSH Alkaline Phosphatase / metabolism Animals Apoptosis / drug effects Bone Resorption / pathology Bone Resorption / prevention & control* Cell Line Cell Proliferation / drug effects Dose-Response Relationship, Drug Female Humans Inhibitory Concentration 50 Isoflavones / isolation & purification Isoflavones / therapeutic use* Mice Osteoblasts / drug effects Osteoblasts / metabolism Osteoblasts / pathology Osteoclasts / drug effects Osteoclasts / metabolism Osteoclasts / pathology Ovariectomy Plant Roots / chemistry Rats Rats, Sprague-Dawley Receptors, Estrogen / metabolism Sophora / chemistry
IF 2.33
Times Cited 16
WOS Category PHARMACOLOGY & PHARMACY CHEMISTRY, MEDICINAL
Resource
Human and Animal Cells